Benzinga | Dec 13, 2021 06:34AM EST

RBC Capital Downgrades IGM Biosciences to Sector Perform, Lowers Price Target to $51

RBC Capital analyst Brian Abrahams downgrades IGM Biosciences (NASDAQ:IGMS) from Outperform to Sector Perform and lowers the price target from $90 to $51.